secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001447362-25-000030
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Biosciences FY 2024 revenue up 51% to $332M, net income $18.2M vs loss; 2025 outlook $280-295M
--------------------------------------------------------------------------------

- Full-year 2024 revenue $332.1M (+51% YoY); test reports 96,071 (+36% YoY).
- Net income $18.2M (incl. $50.3M stock comp) vs net loss $57.5M in 2023.
- Adjusted EBITDA $75.0M vs -$4.4M in 2023; cash $293.1M, up $50M.
- TissueCypher Barrett's Esophagus test reports surged 130% to 20,956; dermatology reports up 17%.
- 2025 revenue guidance $280-295M, below 2024 actual but achieved prior 2025 target a year early.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000144736225000030/0001447362-25-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000144736225000030/cstl-20250227.htm
  HTML page:      https://secwatch.observer/filing/0001447362-25-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer